Decoding the Knacks of Ellagitannin Lead Compounds to Treat Nonalcoholic Fatty Liver Disease using Computer-aided Drug Designing
Overall, ellagitannin was identified as the best druggable target with the best therapeutics profile. The findings of our study can pave the way for the development of a new drug against NALFD.
Authors
- Zhanyou Chi (ORCID: https://orcid.org/0000-0002-9374-0328)
- Wadi B. Alonazi (ORCID: https://orcid.org/0000-0002-3850-4437)
- Hina J Shahid (ORCID: https://orcid.org/0000-0002-3987-929X)
- Muhammad Ibrahim (ORCID: https://orcid.org/0000-0001-8862-5192)
Institutions
- Dalian University of Technology (CN)
- King Saud University (SA)
- Dalian University (CN)
- China National Rice Research Institute (CN)
- University of Business and Technology (SA)
- State Key Laboratory of Rice Biology
- Zhejiang University (CN)
Publication Details
- Journal
- Current Computer - Aided Drug Design
- Published
- 2024-10-08
- DOI
- https://doi.org/10.2174/0115734099325555240927054614
- Citations
- 1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- King Saud University